Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 1, 2009, Pages 64-70

  Mathias, A A ^a   West, S ^a   Hui, J ^a   Kearney, B P ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; ELVITEGRAVIR; LIVER ENZYME; MIDAZOLAM; RITONAVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME SUBSTRATE; FATIGUE; FEMALE; FETUS DEATH; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; QUINOLONES; RITONAVIR; YOUNG ADULT;

EID: 57749197592     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.168     Document Type: Article

References (24)

1. Shulman, N. et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob. Agents Chemother. 46, 3907-3916 (2002).
2. Katlama, C. et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials [abstract 164LB]. In 12th Conference on Retroviruses and Opportunistic Infections, 22-25 February 2005 (Boston, MA, 2005).
3. Malan, N. et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089 [abstract 107LB]. 13th Conference on Retroviruses and Opportunistic Infections, 5-9 February 2006 (Denver, CO, 2006).
4. Kearney, B.P. et al. Pharmacokinetics/pharmacodynamics of GS-9137 an HIV integrase inhibitor [oral presentation]. 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006 (Lisbon, Portugal, 2006).
5. DeJesus, E. et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43, 1-5 (2006).
6. Zolopa, A.R. et al. The HIV integrase inhibitor GS-9137 has potent antiretroviral activity in treatment-experienced patients [oral presentation 143LB]. 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007 (Los Angeles, CA, 2007).
7. Kearney, B.P. et al. Pharmacokinetics/pharmacodynamics of GS-9137 an HIV integrase inhibitor in treatment-naïve and experienced patients [abstract 73]. 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006 (Lisbon, Portugal, 2006).
8. Zhou, S. et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44, 279-304 (2005).
9. Obach, R.S., Walsky, R.L. & Venkatakrishnan, K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 35, 246-255 (2007).
10. Ernest, C.S. II, Hall, S.D. & Jones, D.R. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther. 312, 583-591 (2005).
11. Thummel, K.E. et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59, 491-502 (1996).
12. Prezista (darunavir) tablets [US prescribing information]. Raritan, NJ: Tibotec, 2006.
13. Aptivus (tipranavir) capsules, 250 mg [US prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, 2006.
14. KALETRA (lopinavir/ritonavir) tablets (lopinavir/ritonavir) oral solution [US prescribing information]. North Chicago, IL: Abbott Laboratories, 2007.
15. Mathias, A., Hinkle, J., Enejosa, J., Piliero, P.J. & Kearney, B.P. Lack of pharmacokinetic interaction between ritonavir-boosted GS-9137 (elvitegravir) and tipranavir/r [poster no. TUPDB06]. 4th International AIDS Society Conference and HIV Pathogenesis, Treatment, and Prevention, 22-25 July 2007 (Sydney, Australia, 2007).
16. Mathias, A.A. et al. Lack of pharmacokinetic interaction between ritonavir-boosted GS-9137 (elvitegravir) and darunavir/r [poster no. TUPDB03]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, 22-25 July 2007 (Sydney, Australia, 2007).
17. NORVIR (ritonavir capsules) soft gelatin; (ritonavir oral solution) [US prescribing information]. North Chicago, IL: Abbott Laboratories, 2006.
18. Grasela, D.M., LaCreta, F.P., Kollia, G.D., Randall, D.M. & Uderman, H.D. Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers. Pharmacotherapy 20, 330-335 (2000).
19. Phimmasone, S. & Kharasch, E.D. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin. Pharmacol. Ther. 70, 505-517 (2001).
20. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). In Vivo Drug Metabolism/Drug Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labeling. Rockville, MD (1999).
21. Tsunoda, S.M., Velez, R.L., von Moltke, L.L. & Greenblatt, D.J. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin. Pharmacol. Ther. 66, 461-471 (1999).
22. Ramanathan, S., Shen, G., Cheng, A. & Kearney, B.P. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J. Acquir. Immune Defic. Syndr. 45, 274-279 (2007)
23. Brosnan-Cook, M., Cronin, T., Wintermute, J. & Kagel, J. Importance of complete automated control of SPE conditions in validated LC/MS/MS assay of GS-9137, metabolites and ritonavir in human plasma (Poster ThP198). ASMS Conference on Mass Spectrometry Indianapolis, IN, 3-7 June 2007.
24. Wintermute, J., Brosnan-Cook, M. & Kagel, J. Overcoming autosampler carryover in a validated LC/MS/MS assay of polar, fluorinated GS-9137, its metabolites and ritonavir in human plasma (Poster WP333). ASMS Conference on Mass Spectrometry, Indianapolis, IN, 3-7 June 2007.